Use the hyperlinks, where available to access additional clinical trial information.
A Modular, Phase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy and Safety of RXC004, in Patients With Advanced Solid Tumours That Have Progressed Following Therapy With Current Standard of Care
Redx Pharma Plc
This Phase II, modular, open label, multicentre study will initially open with ring finger protein 43 (RNF43) loss of function (LoF) mutation-positive pancreatic ductal adenocarcinoma (PDAC) (Module 1) and biliary tract cancer (BTC) (Module 2) modules. All participants will receive RXC004 (2mg daily, orally). Denosumab will also be administered via subcutaneous injection at a dose of 120mg once a month.